Logo image of NUVL

NUVALENT INC-A (NUVL) Stock Fundamental Analysis

NASDAQ:NUVL - Nasdaq - US6707031075 - Common Stock - Currency: USD

76.32  -1.92 (-2.45%)

After market: 76.32 0 (0%)

Fundamental Rating

3

Taking everything into account, NUVL scores 3 out of 10 in our fundamental rating. NUVL was compared to 557 industry peers in the Biotechnology industry. NUVL has a great financial health rating, but its profitability evaluates not so good. NUVL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUVL has reported negative net income.
In the past year NUVL has reported a negative cash flow from operations.
NUVL had negative earnings in each of the past 5 years.
In the past 5 years NUVL always reported negative operating cash flow.
NUVL Yearly Net Income VS EBIT VS OCF VS FCFNUVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.21%, NUVL is in the better half of the industry, outperforming 70.38% of the companies in the same industry.
The Return On Equity of NUVL (-29.76%) is better than 78.28% of its industry peers.
Industry RankSector Rank
ROA -27.21%
ROE -29.76%
ROIC N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
NUVL Yearly ROA, ROE, ROICNUVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NUVL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVL Yearly Profit, Operating, Gross MarginsNUVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, NUVL has more shares outstanding
Compared to 5 years ago, NUVL has more shares outstanding
NUVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUVL Yearly Shares OutstandingNUVL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
NUVL Yearly Total Debt VS Total AssetsNUVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

NUVL has an Altman-Z score of 34.04. This indicates that NUVL is financially healthy and has little risk of bankruptcy at the moment.
NUVL has a better Altman-Z score (34.04) than 96.59% of its industry peers.
There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.04
ROIC/WACCN/A
WACCN/A
NUVL Yearly LT Debt VS Equity VS FCFNUVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

NUVL has a Current Ratio of 14.48. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.
NUVL has a Current ratio of 14.48. This is amongst the best in the industry. NUVL outperforms 87.25% of its industry peers.
A Quick Ratio of 14.48 indicates that NUVL has no problem at all paying its short term obligations.
NUVL has a better Quick ratio (14.48) than 87.25% of its industry peers.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.48
NUVL Yearly Current Assets VS Current LiabilitesNUVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

NUVL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -82.16%.
EPS 1Y (TTM)-82.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NUVL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.03% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.26%
EPS Next 2Y-11.05%
EPS Next 3Y5.92%
EPS Next 5Y29.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVL Yearly Revenue VS EstimatesNUVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NUVL Yearly EPS VS EstimatesNUVL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVL Price Earnings VS Forward Price EarningsNUVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVL Per share dataNUVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.05%
EPS Next 3Y5.92%

More info and screens

0

5. Dividend

5.1 Amount

NUVL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVALENT INC-A

NASDAQ:NUVL (6/16/2025, 8:00:01 PM)

After market: 76.32 0 (0%)

76.32

-1.92 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)N/A N/A
Inst Owners107.54%
Inst Owner Change2.46%
Ins Owners2.84%
Ins Owner Change3.71%
Market Cap5.48B
Analysts86.67
Price Target113.12 (48.22%)
Short Float %8.95%
Short Ratio9.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.08%
Min EPS beat(2)-6.58%
Max EPS beat(2)4.41%
EPS beat(4)1
Avg EPS beat(4)-12.29%
Min EPS beat(4)-33.94%
Max EPS beat(4)4.41%
EPS beat(8)4
Avg EPS beat(8)-5.51%
EPS beat(12)7
Avg EPS beat(12)-1.81%
EPS beat(16)8
Avg EPS beat(16)-97.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.21%
EPS NQ rev (1m)-8.04%
EPS NQ rev (3m)-4.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.42
P/tB 5.42
EV/EBITDA N/A
EPS(TTM)-4.39
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0
BVpS14.08
TBVpS14.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.21%
ROE -29.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.01%
ROA(5y)-42.03%
ROE(3y)-20.02%
ROE(5y)-88.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.48
Quick Ratio 14.48
Altman-Z 34.04
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.01%
EPS Next Y-22.26%
EPS Next 2Y-11.05%
EPS Next 3Y5.92%
EPS Next 5Y29.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-87.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.29%
EBIT Next 3Y4.56%
EBIT Next 5YN/A
FCF growth 1Y-168.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.72%
OCF growth 3YN/A
OCF growth 5YN/A